| Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer M Georgieva, JPSN Lima, P Aguiar Jr, G de Lima Lopes Jr, B Haaland Lung Cancer 124, 248-254, 2018 | 68 | 2018 |
| A systematic review and network meta‐analysis of immunotherapy and targeted therapy for advanced melanoma JP da Silveira Nogueira Lima, M Georgieva, B Haaland, G de Lima Lopes Cancer medicine 6 (6), 1143-1153, 2017 | 58 | 2017 |
| Abiraterone or Enzalutamide in Advanced Castration‐Resistant Prostate Cancer: An Indirect Comparison A Chopra, M Georgieva, G Lopes, CM Yeo, B Haaland The Prostate 77 (6), 639-646, 2017 | 41 | 2017 |
| Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer M Georgieva, P Aguiar Jr, JP Lima, B Haaland, G Lopes JOURNAL OF THORACIC ONCOLOGY 12 (11), S2148-S2149, 2017 | 1 | 2017 |
| P2. 07-054 cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer M Georgieva, P Aguiar, JP Lima, B Haaland, G Lopes Journal of Thoracic Oncology 12 (11), S2149-S2150, 2017 | 1 | 2017 |
| Techniques for comparing efficacy and cost-effectiveness of cancer therapies, and improved inference tools M Georgieva Georgia Institute of Technology, 2018 | | 2018 |
| Survival Analysis B Haaland, M Georgieva Methods and Biostatistics in Oncology: Understanding Clinical Research as an …, 2018 | | 2018 |
